Skip to content

Genotype-Informed Intervention Research Workflow

This framework tests whether genotype modifies an intervention's mechanism or response. It does not convert a variant into an intervention recommendation. A defensible study must confirm genotype, define a prospective interaction, characterize the research material and exposure, measure target engagement, and test a prespecified outcome.

The closed loop

confirmed genotype → mechanistic prediction → characterized research material → measured exposure → target engagement → prespecified outcome → revise or falsify

Genotype stratification cannot repair an unmeasured input. Conversely, batch characterization cannot establish a genotype interaction without an appropriate comparison group and functional readout.

Five-step workflow

1. Define one genotype–mechanism interaction

State the molecular defect, the proposed intervention point, and the predicted direction before measuring an outcome. Keep established pharmacogenetics separate from discovery hypotheses.

Variant context Supported boundary Open research question
ABCG2 Q141K (rs2231142) Folding and trafficking defect; selected HDAC-inhibitor rescue conditions are demonstrated in vitro. PPARγ-mediated induction of wild-type ABCG2 is a separate mechanism. Does a specified exposure change Q141K surface trafficking or functional urate flux relative to wild type? Direct rescue by butyrate is unvalidated.
SLC22A12 loss-of-function variants Human loss of URAT1 function can produce renal hypouricemia and exercise-associated complications. What degree and duration of partial target suppression preserves a usable safety margin? Human variants do not supply a dosing ceiling.
HLA-B*58:01 Established allopurinol-hypersensitivity pharmacogenetic context. Discovery interventions must pass their own efficacy and safety gates; they do not inherit comparative safety from avoiding allopurinol.
G6PD deficiency Systemic recombinant uricase can cause severe hemolysis in susceptible patients. Safety of any gut-local UOX configuration remains empirical; luminal location does not establish a safer product.

Use clinical-grade genotyping for trial enrollment and confirm rare or high-consequence variants with an appropriate orthogonal method. Research arrays may generate hypotheses but cannot substitute for trial-grade confirmation.

2. Characterize the research material

Record exact composition, lot or batch identity, production route, storage, and relevant impurities. For biological material, identify the exact strain, construct, formulation, and containment conditions. For a chemical or extract, verify identity and potency with a matrix-appropriate analytical method.

Engineered UOX is research material, not a default intervention source. Each exact configuration must first be built and characterized in its intended host or material. Configuration-level comparison follows only after that evidence exists.

3. Verify exposure

Use the quantification-ladder.md to calibrate a practical batch assay against an appropriate higher-specificity analytical method. Prespecify acceptance limits and how an exposure deviation changes analysis. An out-of-specification batch is documented or excluded under the protocol; it is not corrected through an unscripted exposure change.

If no Tier 1 or Tier 2 method has been validated for the exact analyte and matrix, use a Tier 3 method directly. A cheaper measurement from another matrix is not an exposure substitute.

Input potency, concentration in a sampled matrix, target-compartment exposure, and target engagement are distinct measurements. A certificate, stool metabolite result, or serum biomarker cannot substitute for the other links.

4. Measure target engagement

Choose a readout that distinguishes the proposed mechanism from adjacent explanations. Examples include transporter surface abundance, polarized urate flux, enzyme activity in the intended compartment, pathway-specific transcription, or a validated pharmacodynamic marker. Biomarker movement without target engagement is not mechanistic confirmation.

5. Test the genotype interaction

Use prespecified genotype strata, matched controls, blinded analysis where feasible, and a model or ethics-reviewed study appropriate to the evidence stage. Estimate the genotype-by-exposure interaction directly. Background therapy, diet, renal function, inflammation, and batch variation are covariates rather than post hoc explanations.

Example: ABCG2 Q141K × candidate rescue exposure

A controlled study can compare wild-type, heterozygous, and homozygous Q141K epithelial models under a defined candidate exposure.

Required measurements:

  1. Confirm ABCG2 genotype and comparable baseline expression.
  2. Verify material identity, concentration, stability, and epithelial exposure.
  3. Measure total and surface ABCG2 separately.
  4. Measure basolateral-to-apical urate flux and include an ABCG2-inhibition control.
  5. Test acute functional inhibition separately from chronic transcriptional or trafficking effects.
  6. Advance only if surface trafficking and functional urate flux move coherently without an unacceptable off-target transporter effect.

The design tests a carrier-dependent mechanism; it does not assume that a fiber, butyrate, flavonoid, or chaperone exposure is beneficial.

Example: ABCG2 genotype × luminal UOX

ABCG2 genotype can be a prospective stratification variable only after the UOX configuration itself is characterized. The sequence is:

  1. Build and characterize each exact UOX configuration.
  2. Compare configuration-level activity under the physiological factorial in validation §1.33.
  3. Test antioxidant loss, peroxide handling, and safety in validation §1.36.
  4. Only then design an appropriate genotype-stratified animal or ethics-reviewed human study.

COMP-019's unconditional flat-dose classification is not robust to COMP-044's tested substrate-occupancy and finite-window diagnostics. COMP-044 supplies no replacement dose, ΔSUA, genotype, physiological regime, efficacy, topology or chassis, production, or safety conclusion. Q141K therefore remains a prospective stratification variable, not a response predictor.

Failure modes

  • Unverified input: a null result cannot distinguish absent exposure from mechanism failure.
  • Mechanism substitution: a downstream biomarker is treated as proof of transporter rescue or enzyme activity.
  • Post hoc stratification: genotype groups are created after outcome inspection.
  • Evidence transfer: safety or efficacy from a parent organism, approved drug, or adjacent genotype is assigned to a new material.
  • Single-axis interpretation: renal function, inflammation, background therapy, or compartment-specific exposure is ignored.
  • Model overreach: a computational classification is converted into a dose, clinical effect, or genotype ranking.

Decision rule

A genotype-informed hypothesis advances only when material identity, exposure, target engagement, and the genotype interaction are all interpretable at the same evidence tier. Failure at one link redirects the next experiment; it does not become a carrier-specific recommendation.

Cross-references